为帕金森病患者实施药剂师领导的药物审查服务 患者被录取用于深度大脑刺激
Ugene Sano1, Timothy Jacisin1, Jessica Bente1
1Cooperman Barnabas Medical Center, Livingston, New Jersey.
The Senior care pharmacist
|January 24, 2024
概括
一项由药剂师主导的药物审查显著增加了家庭帕金森病后深度大脑刺激 (DBS) 方案的重新启动率. 这次干预发现了DBS手术后不适当使用多巴胺抗剂的一例.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 临床药房 临床药房
背景情况:
- 深度大脑刺激 (DBS) 是对帕金森病的治疗方法.
- 在DBS后的药物管理对于患者的治疗结果至关重要.
- 多巴胺抗剂可以加剧帕金森病的症状.
研究的目的:
- 为了评估专业药剂师领导的药物评估的临床影响.
- 为了确定多巴胺抗剂在帕金森病患者DBS后给药对多巴胺抗剂的影响.
主要方法:
- 一个单一的中心,两阶段的研究比较前后实施队列.
- 纳入标准:接受帕金森病DBS治疗的18岁以上的患者.
- 主要终点:多巴胺抗剂在DBS后的发病率.
主要成果:
- 服用多巴胺抗剂的发生率:在实施前为1.2%,在实施后为25% (P=0.09).
- 在家重启帕金森病治疗方案:在实施前36.1%与实施后100% (P=0.021).
- 晚期动力障碍,停留时间,坐人或束没有显著差异.
结论:
- 药剂师主导的药物审查发现了一个DBS后不适当药物的案例.
- 该服务显著增加了重启家庭帕金森病药物治疗方案的速度.
- 可能需要进一步的研究来优化DBS后的药物管理.
更多相关视频
06:32Author Spotlight: Automated Deep Brain Stimulation for Parkinson's Disease - Exploring the Possibilities and Challenges of Home Monitoring
Published on: July 14, 2023
1.3K
07:14A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
14.7K
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547
Drug Therapy
44
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
44
